Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
RIGL Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with significant year-over-year sales growth across key products, despite a slight net income decline due to higher R&D and operational expenses. The Q&A section reveals management's strategic focus on hematology/oncology, with promising developments for R289. Although some details were unclear, the overall sentiment is positive, supported by a robust revenue increase and strategic product focus. Given the company's small-cap status, the stock is likely to react positively, falling into the 2% to 8% range over the next two weeks.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates strong financial performance with significant revenue and net income growth, a raised revenue guidance for 2025, and strategic product development plans. Despite some uncertainties in global market access and management's vague responses in the Q&A, the overall sentiment is positive due to the raised guidance and strong financial metrics. The market cap suggests a moderate reaction, leading to a predicted stock price movement of 2% to 8%.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlighted strong financial performance with record revenue and net income, a raised revenue guidance for 2025, and significant product sales growth. Despite some uncertainties in product development and strategic collaborations, the market reacted positively to the optimistic guidance and financial discipline. The Q&A revealed management's cautious optimism and focus on strategic growth, without major negative surprises. Given the company's small-cap status, the positive financial results and guidance are likely to drive a stock price increase in the short term.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call reveals strong financial performance with a 76% increase in net product sales and a significant net income turnaround. The company's strategic partnerships and product demand growth, particularly for GAVRETO, are positive indicators. Despite some risks in strategic execution and global expansion, the optimistic guidance and financial discipline suggest a positive stock price movement. The market cap indicates a potential for notable reaction, but not extreme, leading to a 'Positive' sentiment.
RIGL Slides
RIGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
